Diagnostics, Diagnosis Technology Offers Page 3

Universidad de Alcalá-OTRI posted this:

The research group in Bioelectrochemistry and Biosensors of the University of Alcalá in collaboration with the Textile Industry Research Association (AITEX) has developed an electrochemical sensor of magnesium (Mg2 +) and a construction method based on the formation of a polymeric three-dimensional network that allows the entrapment / immobilization of a selective indicator for Mg2 +, eriochrome black T, by the use of a crosslinking agent and a polymer. The combination of these three reagents allows the construction of the sensor on any conductive surface, avoiding the electro polymerization of the indicator. The resulting sensor allows to measure MG2 + in any type of samples, without the need to add organic salts, additives or organic solvents. The quantification of Mg2 + is done directly by incubating the sensor in the sample containing the analyte, resulting in a modification of the amperometric signal proportional to its concentration. This method has many applications especially in health and biomedical sector since Mg2 + participates in such important activities as neuronal, neuromuscular transmission, or regulation of blood pressure and plays a key role in various pathologies such as vascular and migraines headache. The group is looking for companies in the agro-food, bio-sanitary and environmental sectors, with the aim of reaching technical collaboration agreements, commercial agreements or patent licenses.
Development and method of construction of a new electrochemical sensor of Magnesium (Mg2 +), without the need to add organic salts, additives or organic solvents to the sample

IMIM Institut Recerca Hospital del Mar posted this:

Up to date there is not any technology for detecting the risk to suffer atypical fractures related to long-term treatment with bone remodelling inhibitors. The invention will be of usefulness for individualize treatments in patients treated with bone remodelling inhibitors by detecting the individual risk of suffering atypical fractures. The invention is planned to be included into an in-vitro diagnostic tool for the atypical fracture, which will be included into standard disease management protocols and therefore used routinely by physicians prior to and after the prescription of bone remodelling drugs and further osteoporosis drugs. Osteoporosis is a progressive bone disease with a characteristic decrease in bone mass and density which can lead to an increased risk of fracture. There are two types of osteoporosis: •Type 1: most common in women after menopause, named postmenopausal osteoporosis •Type 2: Senile osteoporosis, occurs mostly after age of 75 years and has equally effect in women and in men Based on the WHO diagnostic criteria, approximately 22 million women and 5.5 million men aged between 50 and 84 years had osteoporosis in the European Union (EU) in 2010, whilst osteoporosis can be found in the list of 10 most important diseases named by the WHO. Due to changes in population demography, the number of men and women with osteoporosis might rise from 27.5 million in 2010 to 33.9 million in 2025, corresponding to an increase of 23%. The number of new fractures in the EU in 2010 was estimated at 3,5 million cases, in between these approximately 620.000 hip fractures, 520.000 vertebral fractures, 560.000 forearm fractures and 1.800.000 fractures of i.e. pelvis, rib, humerus, tibia, fibula, clavicle, scapula, sternum, and other femoral fractures. Two thirds of all fractures occurred in women. In 2010, the number of deaths causally related to fractures was estimated at 43.000. The corresponding cost of osteoporosis in the EU, also in 2010 figures, including pharmacological intervention, was estimated at €37 billion out of which costs of treating fractures represented 66%, pharmacological prevention 5% and long term fracture care 29%. The total health burden was estimated at 1 180 000 lost Quality Adjusted Life Years (QALY) for the EU. The total cost in the EU might rise from €98 billion in 2010 to €120 billion Euro in 2025. The use of osteoporosis drugs has increased considerably. Approved pharmacological interventions (bisphosphonates, strontium ranelate, raloxifene, denosumab and parathyroid hormone peptides) are widely available but their use is restricted by reimbursement policies. Alendronate (a bisphosphonate) is the most commonly prescribed agent, accounting for approximately a quarter of the total value of sales. The potential users/partners are pharmaceutical companies, excluding pure generic companies (lacking development resources, relevant lobbying and sales channel to the policy makers and practitioner) selling drugs in the indication osteoporosis